Cybin Inc. Common Stock Total Liabilities
Cybin Inc. Common Stock total liabilities. Based on the latest financial reports, Cybin Inc. Common Stock (HELP) has total liabilities worth $22.20 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Cybin Inc. Common Stock liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cybin Inc. Common Stock (2017–2025)
Total liabilities of Cybin Inc. Common Stock from 2017 to 2025. This chart illustrates how Cybin Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Cybin Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Cybin Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Cybin Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Resimac Group Ltd
AU:RMC
|
Australia | AU$16.25 Billion |
|
KS Terminals Inc
TW:3003
|
Taiwan | NT$1.82 Billion |
|
Tatry Mountain Resorts a.s.
PR:TMR
|
Czech Republic | Kč453.90 Million |
|
Lantronix Inc
NASDAQ:LTRX
|
USA | $41.06 Million |
|
Cathay Consolidated Inc
TW:1342
|
Taiwan | NT$1.57 Billion |
|
Eaton Vance California MBF
NYSE MKT:EVM
|
USA | $120.49 Million |
|
CItech Co Ltd
KO:004920
|
Korea | ₩28.62 Billion |
|
Trimegah Securities Tbk
JK:TRIM
|
Indonesia | Rp3.30 Trillion |
Liability Composition Analysis (2017–2025)
This chart breaks down Cybin Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cybin Inc. Common Stock total assets.
Liquidity & Leverage Metrics
Cybin Inc. Common Stock Total Liabilities Ratios Explained
Cybin Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cybin Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cybin Inc. Common Stock (2017–2025)
The table below shows the annual total liabilities of Cybin Inc. Common Stock from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $21.42 Million | +112.14% |
| 2024-03-31 | $10.10 Million | +78.28% |
| 2023-03-31 | $5.66 Million | -28.39% |
| 2022-03-31 | $7.91 Million | +31.93% |
| 2021-03-31 | $5.99 Million | +2179.09% |
| 2020-03-31 | $263.00K | +1826.32% |
| 2019-03-31 | $13.65K | -14.30% |
| 2018-03-31 | $15.93K | -89.40% |
| 2017-03-31 | $150.29K | -- |
About Cybin Inc. Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical tr… Read more